Clinical Trials Logo

Clinical Trial Summary

Primary liver cancers are the sixth most common malignancies worldwide, with hepatocellular carcinoma (HCC) accounting for approximately 80% of them. The Barcelona Clinic Liver Cancer (BCLC) classification is widely used in the management of HCC. At the time of diagnosis, fewer than 30% of the patients qualify for resection or transplant due to the large size or multiplicity of the lesions, background chronic liver disease, and other comorbidities. However, the recent spread of surveillance has led to early detection of hepatocellular carcinoma (HCC), and the chance of receiving local treatment has increased. There are several options to treat small HCCs, including surgical resection, chemical ablation, transplantation, and percutaneous ablation (RFA/MWA). Today, percutaneous ablation plays a key role in the treatment of early-stage HCC because it is less invasive than surgical resection and has a good efficacy. However, targeting of lesions under USG alone may be misleading as there may be an enhancing component which is not seen on plain ultrasound. To overcome this problem contrast enhanced ultrasound may be used intra-procedurally, however conventional ultrasound contrast agents show washout by 5 minutes from the system. In this study, the investigators prospectively analyze patients undergoing ablation with the help of precise needle placement using a Kupffer phase ultrasound contrast agent (perfluorobutane) and their post procedure response assessment.


Clinical Trial Description

International status: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver with increasing incidence due to hepatitis B and C viruses . Ultrasound (USG) with, or without alpha feto-protein levels is a standard tool for surveillance of HCC. However, it leads to suboptimal detection rate and false referrals in the US . Use of an ultrasound contrast agent can be helpful in surveillance and diagnosis of focal liver lesions . Second generation ultrasound contrast agents like sulfur hexafluoride (SonoVue), perflutren lipid (Definity) and perfluorobutane (Sonazoid) are microbubbles composed of a phospholipid shell encompassing a low-solubility gas . The characteristic property of Sonazoid is its ability to accumulate in the reticuloendothelial system (such as the Kupffer cells in the liver) for a sustained period of time (up to 60 mins), which is not seen with other second generation contrast agents . Malignant liver lesions do not contain Kupffer cells so these lesions appear hypoechoic in the Kupffer phase (10-60 minutes) . CEUS has been previously used for targeting of lesions for radiofrequency ablation, however the contrast agent used in the study was Definity . CEUS with Sonazoid has been frequently used in Japan, South Korea and Norway for diagnosis and surveillance. Diagnosis with Sonazoid involves the vascular phase (10 sec to 5 minutes) and the Kupffer phase (10-60 minutes). The vascular phase shows the tumor vascularity and the Kupffer phase shows the absence of reticuloendothelial cells in the lesion (2-4). In case of a new lesion detected in the Kupffer phase or a doubt regarding a previously detected lesion, defect reperfusion imaging can be done for confirmation and diagnosis . In a comparison between SonoVue and Sonazoid in diagnosis of liver lesions, Sonazoid was not inferior to SonoVue in diagnosis and significantly better in detecting lesions during whole liver scanning . A study was done using Sonazoid enhanced ultrasound for targeting lesions not detected by conventional USG for ablation therapy, and it was found that CEUS detected 97% of the viable tumours compared to 83% by conventional USG. Furthermore, 93% of the lesions which were not detected on conventional USG were treated successfully using late phase of the contrast agent as a guiding tool . However, CEUS using Sonazoid was not used to assess treatment response in this study. A meta-analysis assessing the treatment response after radiofrequency ablation of HCC using CEUS concluded that technical success was higher with Sonazoid compared to other agents . National status: A study evaluated the role of CEUS in guiding RFA of HCC, however the contrast used was SonoVue and no comparison was made of the post op CEUS with routine 1 month imaging . The purpose of this study is to evaluate role of perfluorobutane in guiding ablation (RFA/MWA) of HCC and to compare treatment response two hours post procedure using the same ultrasound contrast agent with routine follow up CT/MRI at 1 month post procedure. - Why this study- Sonazoid is available in only limited countries as of now (Japan, South Korea, Norway) - So only limited efficacy studies have been done and none in India. - Also, no study as yet has simultaneously evaluated role of Sonazoid in both lesion targeting as well as response assessment. - Hypothesis- Immediate post-procedure CEUS with Sonazoid is not inferior to routine contrast CT/MRI at 1 month follow-up for response assessment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05068076
Study type Interventional
Source Institute of Liver and Biliary Sciences, India
Contact Amar Mukund, MBBS, MD
Phone 09350672277
Email [email protected]
Status Recruiting
Phase N/A
Start date October 4, 2021
Completion date March 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Active, not recruiting NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Recruiting NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Active, not recruiting NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Recruiting NCT03746704 - Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Participants With Advanced PD-L1 Positive Malignancies Phase 1
Recruiting NCT04780802 - Balloon Assisted Transarterial Therapy for Hepatocellular Carcinoma N/A
Recruiting NCT04767906 - Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors Phase 2
Recruiting NCT04641637 - Substudy: Interconnection of Arterial Tumor Feeders Through Tumor Sinusoid in HCC N/A
Not yet recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Active, not recruiting NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2
Terminated NCT03219372 - Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence Phase 2
Completed NCT01908426 - Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Phase 3
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Recruiting NCT04080154 - Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma Phase 2